AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Sucampo, Abbott report Phase III data for lubiprostone in CIC Japanese patients.
(From Pharma)
M2PHARMA-November 30, 2010-Sucampo, Abbott report Phase III data for lubiprostone in CIC Japanese patients (C)2010 M2 COMMUNICATIONS http://www.m2.com
30 November 2010 - US Sucampo Pharmaceuticals Inc (NASDAQ: SCMP) and Abbott Laboratories (NYSE: ABT) reported today encouraging top-line data from a 48-week Phase III long-term safety and efficacy study of lubiprostone in Japanese patients with chronic idiopathic constipation (CIC).
The trial demonstrated that lubiprostone was safe and well-tolerated, the parties added.
This long-term Phase III safety trial was an open-label, multi-centre study in which Japanese CIC patients received …
-
- Lubiprostone successfully completes long-term Phase III safety trial in...
-
News wire article from: Chemical Business Newsbase
November 30, 2010
700+ words
-
- Lubiprostone successfully completes Phase III efficacy trial in Japanese...
-
News wire article from: Chemical Business Newsbase
June 10, 2010
700+ words
-
- Lubiprostone successfully completes Phase III efficacy trial in Japanese...
-
News wire article from: Chemical Business Newsbase
June 8, 2010
700+ words
-
- Leuplin's successor enters phase III in the USA: Takeda, Millennium.
-
News wire article from: Chemical Business Newsbase
November 15, 2010
700+ words
-
- Alexion reports positive results from AEGIS registration study of Soliris in...
-
News wire article from: Chemical Business Newsbase
December 8, 2008
700+ words
